Precys

Precys is a precision medicine company dedicated to advancing drug discovery through the mapping of functional disease networks. Founded by leading scientists from UCSF and UCSD, the company utilizes a proprietary platform that integrates large-scale proteomics and genomics to identify novel therapeutic targets and biomarkers. Their approach focuses on deciphering the complex protein-protein interaction (PPI) networks that drive diseases such as cancer, viral infections, and neurological disorders. By moving beyond static genomic sequencing to dynamic molecular maps, Precys aims to accelerate the development of more effective, targeted therapies. The company's technology is rooted in pioneering research from the Quantitative Biosciences Institute (QBI) and the University of California system.